JP5926821B2 - ２−アリールベンゾフラン−７−カルボキサミド系化合物、その製造方法および用途 - Google Patents
２−アリールベンゾフラン−７−カルボキサミド系化合物、その製造方法および用途 Download PDFInfo
- Publication number
- JP5926821B2 JP5926821B2 JP2014555927A JP2014555927A JP5926821B2 JP 5926821 B2 JP5926821 B2 JP 5926821B2 JP 2014555927 A JP2014555927 A JP 2014555927A JP 2014555927 A JP2014555927 A JP 2014555927A JP 5926821 B2 JP5926821 B2 JP 5926821B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- methyl
- mmol
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210028895.0A CN103242273B (zh) | 2012-02-09 | 2012-02-09 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
| CN201210028895.0 | 2012-02-09 | ||
| PCT/CN2013/070410 WO2013117120A1 (zh) | 2012-02-09 | 2013-01-14 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511942A JP2015511942A (ja) | 2015-04-23 |
| JP5926821B2 true JP5926821B2 (ja) | 2016-05-25 |
Family
ID=48922178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555927A Active JP5926821B2 (ja) | 2012-02-09 | 2013-01-14 | ２−アリールベンゾフラン−７−カルボキサミド系化合物、その製造方法および用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9533965B2 (https=) |
| EP (1) | EP2813495B1 (https=) |
| JP (1) | JP5926821B2 (https=) |
| CN (1) | CN103242273B (https=) |
| BR (1) | BR112014019402B1 (https=) |
| CA (1) | CA2863988C (https=) |
| RU (1) | RU2583900C2 (https=) |
| WO (1) | WO2013117120A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102627620B (zh) * | 2012-04-10 | 2015-12-16 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
| PL2938598T3 (pl) | 2012-12-31 | 2017-05-31 | Cadila Healthcare Limited | Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy) |
| CN105272936B (zh) * | 2014-05-27 | 2019-05-17 | 中国科学院上海药物研究所 | 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途 |
| CN109134409B (zh) * | 2017-06-14 | 2023-09-29 | 中国科学院上海药物研究所 | 盐酸美呋哌瑞多晶型物及其制备方法与应用 |
| CN111320596B (zh) * | 2018-12-14 | 2024-07-05 | 甫康（上海）健康科技有限责任公司 | 盐酸美呋哌瑞多晶型物及其制备方法 |
| US20230094843A1 (en) * | 2019-12-31 | 2023-03-30 | Fukang (Shanghai) Health Technology Co., Ltd | Pharmaceutical combination for treating tumors and application thereof |
| JP2023514794A (ja) * | 2020-02-24 | 2023-04-10 | フーカン（シャンハイ） ヘルス テクノロジー カンパニー、 リミテッド | ポリａｄｐリボースポリメラーゼ阻害剤の抗コロナウイルス応用 |
| WO2024187321A1 (zh) * | 2023-03-10 | 2024-09-19 | 甫康（上海）健康科技有限责任公司 | 含有egfr抑制剂的药物组合物及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87451A0 (en) | 1987-09-04 | 1989-01-31 | Tanabe Seiyaku Co | Benzofuran derivatives,their preparation and pharmaceutical compositions containing them |
| JP2002515488A (ja) * | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法 |
| DE59911249D1 (de) * | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| DK1131301T3 (da) * | 1998-11-17 | 2006-01-09 | Abbott Gmbh & Co Kg | 2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf |
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| DE10351315A1 (de) | 2003-10-31 | 2005-06-16 | Aventis Pharma Deutschland Gmbh | 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung |
| DK1794163T3 (da) * | 2004-09-22 | 2010-04-12 | Pfizer | Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| CA2647373C (en) * | 2006-05-02 | 2014-03-18 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| DK2120579T3 (da) * | 2006-12-28 | 2014-02-03 | Abbvie Inc | Inhibitorer af poly(ADP-ripose)polymerase |
| WO2008098978A2 (en) | 2007-02-16 | 2008-08-21 | Glaxo Group Limited | Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor |
| WO2009009417A2 (en) | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| WO2009099736A2 (en) * | 2008-02-06 | 2009-08-13 | Lead Therapeutics, Inc. | Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp) |
| GB0806656D0 (en) | 2008-04-11 | 2008-05-14 | Karobio Ab | Novel estrogen receptor ligands |
| US8569336B2 (en) * | 2008-11-10 | 2013-10-29 | Ling Tong | Compounds for the treatment of inflammatory disorders |
| WO2011022679A2 (en) | 2009-08-20 | 2011-02-24 | University Of Tennessee Research Foundation, The | Benzofuran cannabinoid compounds and related methods of use |
| GB0919380D0 (en) * | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
| CN102627620B (zh) * | 2012-04-10 | 2015-12-16 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
-
2012
- 2012-02-09 CN CN201210028895.0A patent/CN103242273B/zh active Active
-
2013
- 2013-01-14 US US14/375,742 patent/US9533965B2/en active Active
- 2013-01-14 JP JP2014555927A patent/JP5926821B2/ja active Active
- 2013-01-14 CA CA2863988A patent/CA2863988C/en active Active
- 2013-01-14 WO PCT/CN2013/070410 patent/WO2013117120A1/zh not_active Ceased
- 2013-01-14 RU RU2014132159/04A patent/RU2583900C2/ru active
- 2013-01-14 BR BR112014019402-5A patent/BR112014019402B1/pt active IP Right Grant
- 2013-01-14 EP EP13746724.7A patent/EP2813495B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2813495B1 (en) | 2016-09-28 |
| CN103242273A (zh) | 2013-08-14 |
| BR112014019402B1 (pt) | 2020-12-15 |
| BR112014019402A8 (pt) | 2017-07-11 |
| JP2015511942A (ja) | 2015-04-23 |
| CA2863988C (en) | 2016-03-22 |
| US20150018542A1 (en) | 2015-01-15 |
| BR112014019402A2 (https=) | 2017-06-20 |
| US9533965B2 (en) | 2017-01-03 |
| CN103242273B (zh) | 2015-06-03 |
| RU2583900C2 (ru) | 2016-05-10 |
| EP2813495A4 (en) | 2015-06-17 |
| RU2014132159A (ru) | 2016-03-27 |
| EP2813495A1 (en) | 2014-12-17 |
| WO2013117120A1 (zh) | 2013-08-15 |
| CA2863988A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5926821B2 (ja) | ２−アリールベンゾフラン−７−カルボキサミド系化合物、その製造方法および用途 | |
| CN102378753B (zh) | 纤溶酶原激活物抑制因子-1抑制剂 | |
| KR100618074B1 (ko) | 벤즈아미드 유도체 및 이것의 사이토킨 억제제로서 용도 | |
| CN113181339B (zh) | 一种醛基类化合物的药物用途 | |
| CN105037355A (zh) | Wnt信号传导途径的吲唑抑制剂及其治疗用途 | |
| WO2008059867A1 (en) | Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | |
| KR20010099609A (ko) | 사이토킨의 생성 억제제로서 유용한 아미드 유도체 | |
| KR20090083491A (ko) | ２－퓨란 카르복시산 하이드라지드 화합물 및 그것을 함유하는 의약 조성물 | |
| WO2002006264A1 (en) | Lipid-rich plaque inhibitors | |
| TW200417546A (en) | New compounds | |
| CN103842350B (zh) | 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用 | |
| CN108069954B (zh) | 含no供体的喹唑啉酮化合物 | |
| CN102993093A (zh) | N,n’-二取代二苯基硫脲类化合物、其制备方法和用途 | |
| Schuler et al. | Boronic acid-containing aminopyridine-and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability | |
| CN101544631B (zh) | 吡唑类5-脂氧酶小分子抑制剂及其制备方法、药物组合物和应用 | |
| CN110099685A (zh) | 溴结构域抑制剂 | |
| EP3684354B1 (en) | Xpa inhibitor compounds and their use | |
| CN104945411A (zh) | 噻吩并[3,2-c]吡啶类化合物、其制备方法及应用 | |
| TW202412778A (zh) | 一種脯氨醯羥化酶抑制劑及其用途 | |
| CN102532113B (zh) | 芳基脲衍生物 | |
| CN111018686B (zh) | 6-苄亚基-2-芳基乙炔基环己烯酮衍生物及其制备方法和医药用途 | |
| WO2021182490A1 (ja) | イミダゾピリジノン化合物又はその塩の結晶 | |
| US20090030049A1 (en) | Medicament for genital herpes | |
| CN104370890B (zh) | 一类喹唑啉类化合物及其作为免疫抑制剂的应用 | |
| WO2012174926A1 (zh) | N-取代异丙二甲薁磺酰胺类衍生物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151030 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160412 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160422 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5926821 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |